Lipid‐lowering agents use and systemic and oral inflammation in overweight or obese adult Puerto Ricans: the San Juan Overweight Adults Longitudinal Study (SOALS). (11th December 2015)

• Record Type: Journal Article
• Authors: Andriankaja, Oelisoa M.; Jiménez, James J.; Muñoz‐Torres, Francisco J.; Pérez, Cynthia M.; Vergara, José L.; Joshipura, Kaumudi J.
• Is Part Of: Journal of clinical periodontology. Volume 42:Number 12(2015:Dec.)
• Page Start: 1090
• Page End: 1096
• Publication Date: 2015-12-11
• Subjects: hs‐CRP -- lipid‐lowering agents -- periodontitis -- statins -- systemic inflammation; Periodontics -- Periodicals; 617.6
• DOI: 10.1111/jcpe.12461
• Languages: English
• ISSNs: 0303-6979

Abstract

Abstract: The effects of lipid‐lowering agents (LLA) on reducing systemic and oral inflammation have not been evaluated. Objective: To assess the association of LLA use with high‐sensitivity C‐reactive protein (hs‐CRP) and oral inflammation. Design: Cross‐sectional analysis using baseline data from 1300 overweight/obese participants aged 40–65 years, recruited for the ongoing San Juan Overweight Adults Longitudinal Study. Serum hs‐CRP was measured by ELISA, gingival/periodontal inflammation was evaluated as bleeding upon probing (BOP), and LLA was self‐reported. Separate logistic models were performed for systemic and oral inflammation. Results: In all, 24% participants reported history of dyslipidaemia, of which, 50.3% self‐reported LLA use. Sixty percent of the participants had elevated hs‐CRP (>3 mg/dl) and 50% had high BOP (defined as at or above the median: 21%). After adjusting for age, gender, smoking, HDL‐C, physical activity, diabetes, blood pressure medications, and percent body fat composition, LLA users had significantly lower odds of elevated hs‐CRP compared to LLA non‐users (OR = 0.58; 95% CI: 0.39–0.85). After adjusting for age, gender, smoking status, educational level, mean plaque index and percent body fat, LLA users had significantly lower odds of high BOP compared to LLA non‐users (OR = 0.62; 95% CI: 0.42–0.91). Conclusions: Lipid‐lowering agents may reduce both systemic and oral inflammatory responses.